Table 1.
Clinical outcomes and most common AEs (≥3 grade).
Fig 1.
(a) Three transitional health states. (b) Markov model used to compare two treatment strategies for mRCC.
Table 2.
Key parameters input in the model.
Fig 2.
Tornado diagram shows incremental cost-effectiveness ratio (ICER) of anlotinib vs. sunitinib for different input parameters.
Fig 3.
The results of probabilistic sensitivity analysis.
(a) Scatterplot of the ICER between the anlotinib and sunitinib group. (b) The cost-effectiveness acceptability curves for anlotinb compared to the sunitinib at different willingness-to-pay thresholds.